JOP20210014A1 - تركيبات مضادات fcrn وطرق استخدامها - Google Patents

تركيبات مضادات fcrn وطرق استخدامها

Info

Publication number
JOP20210014A1
JOP20210014A1 JOP/2021/0014A JOP20210014A JOP20210014A1 JO P20210014 A1 JOP20210014 A1 JO P20210014A1 JO P20210014 A JOP20210014 A JO P20210014A JO P20210014 A1 JOP20210014 A1 JO P20210014A1
Authority
JO
Jordan
Prior art keywords
compositions
methods
fcrn antibodies
fcrn
antibodies
Prior art date
Application number
JOP/2021/0014A
Other languages
English (en)
Inventor
Zhongli Zhang
Narinder Singh
Eva Williams
Siddhesh Patil
Louis Gregory St
Original Assignee
Zhongli Zhang
Momenta Pharmaceuticals Inc
Louis Gregory St
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongli Zhang, Momenta Pharmaceuticals Inc, Louis Gregory St filed Critical Zhongli Zhang
Publication of JOP20210014A1 publication Critical patent/JOP20210014A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلّق الاختراع الحالي ويتميّز بتركيبات صيدلانية مستقرة تحتوي على جسم مضاد لـ FcRn.
JOP/2021/0014A 2018-07-20 2019-07-19 تركيبات مضادات fcrn وطرق استخدامها JOP20210014A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701467P 2018-07-20 2018-07-20
PCT/US2019/042597 WO2020023310A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
JOP20210014A1 true JOP20210014A1 (ar) 2021-01-19

Family

ID=69180697

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2021/0014A JOP20210014A1 (ar) 2018-07-20 2019-07-19 تركيبات مضادات fcrn وطرق استخدامها
JOP/2021/0015A JOP20210015A1 (ar) 2018-07-20 2019-07-19 تركيبات مضادات fcrn وطرق استخدامها

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2021/0015A JOP20210015A1 (ar) 2018-07-20 2019-07-19 تركيبات مضادات fcrn وطرق استخدامها

Country Status (15)

Country Link
US (1) US20210299255A1 (ar)
EP (1) EP3826641A4 (ar)
JP (1) JP7457704B2 (ar)
KR (1) KR20210105872A (ar)
CN (1) CN113301903A (ar)
AU (1) AU2019312139A1 (ar)
BR (1) BR112021001017A2 (ar)
CA (1) CA3106669A1 (ar)
CR (1) CR20210088A (ar)
EA (1) EA202190335A1 (ar)
IL (1) IL280280A (ar)
JO (2) JOP20210014A1 (ar)
MX (1) MX2021000790A (ar)
SG (1) SG11202100420UA (ar)
WO (1) WO2020023310A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE063778T2 (hu) 2015-01-30 2024-01-28 Momenta Pharmaceuticals Inc FcRn ellenanyagok és eljárások alkalmazásukra
US11773168B2 (en) 2017-12-13 2023-10-03 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
WO2022221239A1 (en) * 2021-04-12 2022-10-20 Momenta Pharmaceuticals, Inc. Compositions and methods for treating pediatric myasthenia gravis
CN116539488B (zh) * 2023-05-11 2023-11-24 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192528A1 (en) * 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
US20090110681A1 (en) * 2005-03-08 2009-04-30 Pfizer, Inc. Anti-M-CSF Antibody Compositions
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
EP2358392B1 (en) * 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
ES2607489T3 (es) * 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
HUE063778T2 (hu) * 2015-01-30 2024-01-28 Momenta Pharmaceuticals Inc FcRn ellenanyagok és eljárások alkalmazásukra
JP2018527903A (ja) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
IL302288A (en) * 2016-07-29 2023-06-01 Momenta Pharmaceuticals Inc FCRN antibodies and methods of using them

Also Published As

Publication number Publication date
WO2020023310A1 (en) 2020-01-30
AU2019312139A1 (en) 2021-02-04
CR20210088A (es) 2021-09-02
JP7457704B2 (ja) 2024-03-28
KR20210105872A (ko) 2021-08-27
JP2021531346A (ja) 2021-11-18
IL280280A (en) 2021-03-25
JOP20210015A1 (ar) 2021-01-19
BR112021001017A2 (pt) 2021-05-04
EP3826641A4 (en) 2022-04-20
MX2021000790A (es) 2021-07-21
US20210299255A1 (en) 2021-09-30
SG11202100420UA (en) 2021-02-25
EA202190335A1 (ru) 2021-06-11
EP3826641A1 (en) 2021-06-02
CA3106669A1 (en) 2020-01-30
CN113301903A (zh) 2021-08-24

Similar Documents

Publication Publication Date Title
MX2018016364A (es) Anticuerpos anti-pd-l1.
CR20210088A (es) Composiciones de anticuerpos fcrn y métodos de uso de estos
WO2018234793A3 (en) Antibodies
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
PH12020551716A1 (en) Anti-ror antibody constructs
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
WO2016172551A8 (en) METHODS OF IDENTIFYING BACTERIA COMPRISING BINDING POLYPEPTIDES
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
EP3880245A4 (en) COMPOSITIONS AND METHODS FOR CYTOPLASMATIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2022006577A (es) Formulaciones liquidas de tasimelteon y metodos para su uso.
CR20230087A (es) Anticuerpos anti-notch2 y métodos de uso